Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 1.00 |
| ▸ | FPR3 | P25089 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bx 471 Free Base SCHEMBL5972008 | 1.00 | CCR1 (1.00) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL4589100 | 1.00 | CCR1 (1.00) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL30059128 | 1.00 | CCR1 (1.00) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL29416828 | 1.00 | CCR1 (1.00) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL3699446 | 0.99 | CCR1 (1.00) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL30172123 | 0.99 | CCR1 (1.00) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL434321 | 0.99 | CCR1 (1.00) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL6949884 | 0.97 | CCR1 (0.94) | CCR1FPR3GPR65GPR35PTGDR2 | |
| Bx 471 Free Base SCHEMBL6949887 | 0.95 | CCR1 (0.91) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL13035071 | 0.92 | CCR1 (0.85) | CCR1FPR3GPR65GPR35PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119139304-A | Application of targeted CCR1 inhibitor in medicines for treating acute respiratory inflammatory diseases | 浙江大学 | 2024-12-17 | — | — | CN | claimed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | claimed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | claimed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | claimed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | claimed |
| EP-1305047-B1 | NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS IN COMBINATION WITH CYCLOSPORIN A FOR THE TREATMENT OF HEART TRANSPLANT REJECTION | SCHERING AG (DE) | 2006-06-21 | — | — | EP | claimed |
| EP-1423166-B1 | NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PROGRESSIVE RENAL FIBROSIS | SCHERING AG (DE) | 2006-04-19 | — | — | EP | claimed |
| US-20050192282-A1 | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | US | claimed |
| WO-2005077372-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | WO | claimed |
| US-20050043318-A1 | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | SCHERING AKTIEGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | claimed |
| EP-1305047-A2 | NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS IN COMBINATION WITH CYCLOSPORIN A FOR THE TREATMENT OF HEART TRANSPLANT REJECTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-02 | — | — | EP | claimed |
| WO-2003035037-A1 | SOLID PHARMACEUTICAL FORMULATION FOR A PIPERAZINE UREA DERIVATIVE | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | WO | claimed |
| WO-2003013656-A2 | NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PROGRESSIVE RENAL FIBROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-20 | — | — | WO | claimed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | claimed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | claimed |
| US-20020039997-A1 | Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-04 | — | — | US | claimed |
| WO-2002009762-A2 | NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS IN COMBINATION WITH CYCLOSPORIN A FOR THE TREATMENT OF HEART TRANSPLANT REJECTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | WO | claimed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | claimed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | claimed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020039997-A1 | Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection | CCR1, CCRL2, CCR3 | CCR1 1/4885FPR3 79/4885GPR65 174/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | CCR1 14/4885FPR3 474/4885GPR65 84/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CCR1 364/4885FPR3 85/4885GPR65 321/4885 |
| US-20050192282-A1 | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | CCL2, CCL11, CCL5 | CCR1 13/4885FPR3 690/4885GPR65 159/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | CCR1 4304/4885FPR3 4042/4885GPR65 938/4885 |
| US-20050043318-A1 | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | CCL2, CCR2, CXCL10 | CCR1 14/4885FPR3 474/4885GPR65 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.